Recent 8-K filings for HNGE
Highest-materiality recent filing
Hinge Health Q1 revenue $182M (+47% YoY), EPS $0.41; raises FY guidance to $801M
- Revenue of $182.3M, +47% YoY; GAAP diluted EPS $0.41, non-GAAP $0.45.
- GAAP operating income $32.1M (+144% YoY); non-GAAP operating income $46.2M (+208% YoY).
-
Hinge Health raises FY 2026 revenue guidance to $818-824M, up $20M at midpoint
FY 2026 revenue guided $818-824M, up from prior range; represents 40% YoY growth at midpoint.
-
Teddie Wardi received ~276.9M votes for, ~14.9M withheld; Tyler Sloat received ~291.3M for, ~0.5M withheld.
-
Hinge Health Q1 revenue $182M (+47% YoY), EPS $0.41; raises FY guidance to $801M
Revenue of $182.3M, +47% YoY; GAAP diluted EPS $0.41, non-GAAP $0.45.
-
Hinge Health appoints Tyler Sloat to Board of Directors, effective March 16, 2026
Tyler Sloat appointed as Class I director; term expires at 2026 annual meeting.
-
Hinge Health Q4 revenue $170.7M (+46% YoY); guides FY26 rev $732-742M
Q4 revenue $170.7M (+46% YoY); GAAP diluted EPS $0.37, non-GAAP $0.49.
-
Hinge Health authorizes $250M share repurchase; Q3 free cash flow $118M
Board approved up to $250M repurchase of Class A common stock on Nov 10, 2025.
-
Hinge Health Q3 revenue $154.2M (+53% YoY); raises FY 2025 guidance
Revenue $154.2M vs $100.6M in Q3 2024, +53% YoY; GAAP gross margin 82% vs 79%.
-
Hinge Health lock-up early release triggered; ~1.66M shares unlocked Aug 19
Early release condition satisfied on Aug 6: stock price >120% of IPO price for 5+ days in 10-day window after Q1 earnings (Aug 5).
-
Revenue grew 55% YoY to $139.1M; GAAP gross margin 70%, non-GAAP gross margin 83%.
-
Hinge Health completes IPO of 15.7M shares at $32.00, raising $272.7M in gross proceeds
IPO closed May 23, 2025; 15,715,900 shares of Class A common stock sold at $32.00 per share.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.78 · Most common event earnings